Medicus Pharma director granted 50,000 stock options

Medicus Pharma Ltd. director Ashton William received a grant of stock options as part of his compensation.

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Ashton William received a grant of stock options as part of his compensation. He was awarded options covering 50,000 common shares at an exercise price of $0.3600 per share. The options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year, ending on June 3, 2027. These options expire on June 3, 2031, and following this grant he holds options on 50,000 shares directly.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Ashton William

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 50,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

Key Figures

Options granted: 50,000 options Exercise price: $0.3600 per share Underlying shares: 50,000 common shares +3 more

6 metrics

Options granted 50,000 options Grant to director on June 3, 2026

Exercise price $0.3600 per share Stock option strike price

Underlying shares 50,000 common shares Shares underlying granted options

Expiration date June 3, 2031 Option term end date

Shares following transaction 50,000 options Total options held directly after grant

Vesting schedule 4 quarterly installments over 1 year From June 3, 2026 grant date

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vest quarterly, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "0.3600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest quarterly financial

"The option is scheduled to vest quarterly in four equal installments over one year."

expiration date financial

"expiration_date: "2031-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medicus Pharma (MDCX) report for Ashton William?

Medicus Pharma reported that director Ashton William received a grant of stock options for 50,000 common shares. The award was made on June 3, 2026, as compensation and gives him the right to buy shares at a fixed exercise price in the future.

How many Medicus Pharma stock options were granted to Ashton William?

Ashton William was granted stock options covering 50,000 common shares of Medicus Pharma. This award represents his entire reported option position in this filing, with all 50,000 options held directly following the grant as part of his director compensation package.

What is the exercise price and expiration date of Ashton William’s Medicus Pharma options?

The stock options granted to Ashton William have an exercise price of $0.3600 per common share and expire on June 3, 2031. This means he can choose to purchase shares at $0.3600 anytime before that expiration date, subject to vesting.

How do Ashton William’s Medicus Pharma options vest over time?

The options granted to Ashton William vest quarterly in four equal installments over one year. The grant was made on June 3, 2026, so vesting occurs in four quarterly tranches through June 3, 2027, aligning vesting with continued service as a director.

Does this Form 4 show Ashton William buying or selling Medicus Pharma shares on the market?

The Form 4 shows a grant of stock options to Ashton William, not an open-market buy or sell. The transaction is coded as an award (code A), representing a compensation-related acquisition of derivative securities rather than a market trade in common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ashton William

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		50,000		(1)	06/03/2031	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for William L. Ashton	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)